All In Biotech

Drug Trial Radar · NCT01231607

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Aug 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 917 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

917

Actual

Start

Oct 28, 2010

Primary completion

Feb 1, 2012

Study completion Feb 28, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 20 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

Conditions

  • Androgenetic Alopecia

Interventions

  • 1mg Finasteride activeDrug

    1mg finasteride active, by mouth once daily

  • 0.02mg dutasterideDrug

    0.02mg dutasteride active, by mouth once daily

  • 0.1mg dutasterideDrug

    0.1mg dutasteride active, by mouth once daily

  • 0.5mg dutasterideDrug

    0.5mg dutasteride active, by mouth once daily

  • Finasteride placeboDrug

    finasteride placebo, by mouth once daily

  • Dutasteride placeboDrug

    dutasteride placebo, by mouth once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)Time frame: Baseline and Week 24

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    CABA, Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    La Boca, Buenos Aires, Argentina

  • GSK Investigational Site

    Santiago, Región Metro de Santiago, Chile

  • GSK Investigational Site

    Viña del Mar, Valparaiso, Chile

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Zapopan, Jalisco, Jalisco, Mexico

  • GSK Investigational Site

    Monterrey, Nuevo León, Mexico

  • GSK Investigational Site

    Mazatlan, Sinaloa, Sinaloa, Mexico

  • GSK Investigational Site

    Naucalpan, State of Mexico, Mexico

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima Cercado, Peru

  • GSK Investigational Site

    Lima, Lima Province, Peru

  • GSK Investigational Site

    Makati City, Philippines

  • GSK Investigational Site

    Manila, Philippines

  • GSK Investigational Site

    Quezon City, Philippines

  • GSK Investigational Site

    Quezon City, Philippines

  • GSK Investigational Site

    Tanauan City, Batangas, Philippines

  • GSK Investigational Site

    Moscow, Russia

  • GSK Investigational Site

    Nizhny Novgorod, Russia

  • GSK Investigational Site

    Ryazan, Russia

  • GSK Investigational Site

    Saint Petersburg, Russia

  • GSK Investigational Site

    St'Petersburg, Russia

  • GSK Investigational Site

    Tainan, Taiwan

  • GSK Investigational Site

    Taipei, Taiwan

  • GSK Investigational Site

    Taipei, Taiwan

  • GSK Investigational Site

    Taipei, Taiwan

  • GSK Investigational Site

    Bangkoknoi Bangkok, Thailand

  • GSK Investigational Site

    Chiang Mai, Thailand

  • GSK Investigational Site

    Patumwan Bangkok, Thailand

  • GSK Investigational Site

    Rajthevee Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.